BioSpace News Archive

The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), today announced that they will co-fund the ongoing global pivotal Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. CEPI will provide up to $9.25m in funding.

Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to seven new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data are being presented in a poster session today from the Company’s ongoing Biomarkers of progression in Multiple System Atrophy (bioMUSE) study today at the American Academy of Neurology (AAN) Annual Meeting.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in combination with a wide range of anticancer therapies in the treatment of numerous cancer types at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.

Revelation Biosciences Inc. today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time.

Progenity, Inc. today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting.

AffyImmune Therapeutics, Inc. announced today that it will present an abstract in a poster session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

United Biomedical, Inc.-Asia (UBI-Asia), today announced the publication of a study in the Journal of Clinical Investigation that demonstrates that UBI-Asia’s Multitope SARS-CoV-2 Subunit Vaccine, UB-612, elicited long-lasting B- and T-cell immunity against the Omicron and Delta variants in Phase 1/2 and Phase 1 extension clinical trials.

Outset Medical, Inc., a medical technology company reducing the cost and complexity of dialysis, announced the release of three new data sets related to home dialysis.

Lunit announced the presentation of two abstracts featuring its AI research on cancer treatment at the upcoming American Association for Cancer Research Annual Meeting 2022.